Allakos Inc. (NASDAQ: ALLK)
$1.1600
+0.0100 ( -2.52% ) 218.5K
Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK006 targets Siglec-6, an inhibitory receptor expressed selectively on mast cells. Binding of AK006 to Siglec-6 is designed to activate the native inhibitory function of the receptor which in turn reduces mast cell activation.
Market Data
Open
$1.1600
Previous close
$1.1500
Volume
218.5K
Market cap
$101.85M
Day range
$1.1050 - $1.2200
52 week range
$0.5350 - $3.4050
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 11 | Nov 18, 2024 |
8-k | 8K-related | 12 | Nov 06, 2024 |
10-q | Quarterly Reports | 64 | Nov 06, 2024 |
8-k | 8K-related | 12 | Oct 10, 2024 |
8-k | 8K-related | 39 | Oct 10, 2024 |
4 | Insider transactions | 1 | Sep 12, 2024 |
4 | Insider transactions | 1 | Sep 11, 2024 |
4 | Insider transactions | 1 | Sep 10, 2024 |
4 | Insider transactions | 1 | Sep 10, 2024 |
8-k | 8K-related | 11 | Aug 16, 2024 |